loxapine has been researched along with Agitation, Psychomotor in 41 studies
Loxapine: An antipsychotic agent used in SCHIZOPHRENIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to investigate the efficacy and safety of inhaled loxapine compared with the intramuscular (IM) antipsychotic aripiprazole in acutely agitated patients with schizophrenia or bipolar I disorder." | 9.27 | PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. ( Bukhanovskaya, O; Dobrovolskaya, N; Estrada, G; Montañés, F; Oudovenko, N; Popov, M; San, L; Vieta, E, 2018) |
| "The PLACID trial will assess the efficacy and safety of inhaled loxapine with deep lung absorption compared with the IM antipsychotic, aripiprazole, in acutely agitated patients with schizophrenia or bipolar disorder." | 9.24 | Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. ( Estrada, G; Oudovenko, N; San, L; Vieta, E, 2017) |
| "To evaluate inhaled loxapine for acute treatment of agitation in schizophrenia." | 9.15 | Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. ( Allen, MH; Cassella, JV; Feifel, D; Fishman, R; Kehne, JH; Lesem, MD; Riesenberg, RA; Spyker, DA; Tran-Johnson, TK, 2011) |
| "Inhaled loxapine rapidly reduces acute agitation in patients with schizophrenia or bipolar disorder and is generally well tolerated." | 8.93 | Inhaled loxapine for the urgent treatment of acute agitation associated with schizophrenia or bipolar disorder. ( Pollack, CV, 2016) |
| "To describe the efficacy of inhaled loxapine for the treatment of agitation associated with schizophrenia or bipolar disorder using different examples of effect size (ES)." | 8.88 | Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. ( Citrome, L, 2012) |
| "To describe the efficacy and safety of inhaled loxapine, a new formulation of an older antipsychotic being developed for the treatment of agitation associated with schizophrenia or bipolar disorder." | 8.87 | Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder. ( Citrome, L, 2011) |
| " Using this delivery method, loxapine was assessed for its antiagitation effects in schizophrenia and bipolar I disorder patients." | 7.79 | Inhaled loxapine: a new treatment for agitation in schizophrenia or bipolar disorder. ( Owen, RT, 2013) |
| "Loxapine has been adopted in the management of a wide range of acute disturbances, such as agitation in psychosis." | 6.82 | Fifty years of experience with loxapine for the rapid non-coercive tranquilization of acute behavioral disturbances in schizophrenia patients, and beyond. ( Baloche, E; Corruble, E; Llorca, PM; Nuss, P; P Garay, R, 2022) |
| "Loxapine is a well-established, first-generation antipsychotic agent." | 6.49 | Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. ( Keating, GM, 2013) |
| "The aim of the study was to investigate the efficacy and safety of inhaled loxapine compared with the intramuscular (IM) antipsychotic aripiprazole in acutely agitated patients with schizophrenia or bipolar I disorder." | 5.27 | PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. ( Bukhanovskaya, O; Dobrovolskaya, N; Estrada, G; Montañés, F; Oudovenko, N; Popov, M; San, L; Vieta, E, 2018) |
| " The aim is to include approximately 500 patients with schizophrenia or bipolar disorder who previously received and responded well to inhaled loxapine in the hospital setting." | 5.27 | Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting: protocol for a phase IV, single-arm, open-label trial. ( Baleeiro Teixeira, T; Boldeanu, A; Garcia-Alonso, F; Gil, E, 2018) |
| "The PLACID trial will assess the efficacy and safety of inhaled loxapine with deep lung absorption compared with the IM antipsychotic, aripiprazole, in acutely agitated patients with schizophrenia or bipolar disorder." | 5.24 | Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. ( Estrada, G; Oudovenko, N; San, L; Vieta, E, 2017) |
| "To evaluate inhaled loxapine for acute treatment of agitation in schizophrenia." | 5.15 | Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. ( Allen, MH; Cassella, JV; Feifel, D; Fishman, R; Kehne, JH; Lesem, MD; Riesenberg, RA; Spyker, DA; Tran-Johnson, TK, 2011) |
| "The objective of this study was to assess the efficacy and safety of inhaled loxapine in the treatment of agitation in patients with psychotic disorders." | 5.15 | Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. ( Allen, MH; Cassella, JV; Feifel, D; Lesem, MD; Munzar, P; Ross, R; Spyker, DA; Zimbroff, DL, 2011) |
| " To date, the only formulation administered via a non-intramuscular route with a specific indication for agitation associated with bipolar or schizophrenia is inhaled loxapine." | 4.93 | Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting. ( Citrome, L; Zeller, SL, 2016) |
| "Inhaled loxapine rapidly reduces acute agitation in patients with schizophrenia or bipolar disorder and is generally well tolerated." | 4.93 | Inhaled loxapine for the urgent treatment of acute agitation associated with schizophrenia or bipolar disorder. ( Pollack, CV, 2016) |
| "To describe the efficacy of inhaled loxapine for the treatment of agitation associated with schizophrenia or bipolar disorder using different examples of effect size (ES)." | 4.88 | Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. ( Citrome, L, 2012) |
| "To describe the efficacy and safety of inhaled loxapine, a new formulation of an older antipsychotic being developed for the treatment of agitation associated with schizophrenia or bipolar disorder." | 4.87 | Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder. ( Citrome, L, 2011) |
| "Over 67 days, 1,461 patients were screened in the ED, 269 had bipolar I or schizophrenia, 194 of whom had a contraindication to inhaled loxapine leaving 75 eligible patients; preconsent was obtained in 43 patients." | 3.91 | Study Enrollment When "Preconsent" Is Utilized for a Randomized Clinical Trial of Two Treatments for Acute Agitation in the Emergency Department. ( Cole, JB; Driver, BE; Klein, LR; Mullinax, SZ; Nordstrom, KD; Wilson, MP, 2019) |
| "1 mg of loxapine administered outside the hospital to treat psychomotor agitation related to schizophrenia, bipolar disorder, or schizoaffective disorder." | 3.85 | [New medical approach to out-of-hospital treatment of psychomotor agitation in psychiatric patients: a report of 14 cases]. ( Borraz-Clares, D; Cester-Martínez, A; Cortés-Ramas, JA; Pellicer-Gayarre, M, 2017) |
| " Using this delivery method, loxapine was assessed for its antiagitation effects in schizophrenia and bipolar I disorder patients." | 3.79 | Inhaled loxapine: a new treatment for agitation in schizophrenia or bipolar disorder. ( Owen, RT, 2013) |
| "Inhalative loxapine which will come onto the market shortly, is an important new alternative medication for the treatment of agitation, restlessness and tension in patients with schizophrenia and bipolar disorders." | 3.79 | [Inhalative loxapine: old tried and trusted medication with new indications]. ( Juckel, G, 2013) |
| "Loxapine has the ability to control agitation without affecting spontaneous ventilation." | 2.84 | Loxapine to control agitation during weaning from mechanical ventilation. ( Cohen, Y; Dreyfuss, D; Gaudry, S; Hajage, D; Megarbane, B; Ricard, JD; Salomon, L; Sonneville, R; Sztrymf, B; Van Der Meersch, G; Vodovar, D, 2017) |
| "Loxapine has been adopted in the management of a wide range of acute disturbances, such as agitation in psychosis." | 2.82 | Fifty years of experience with loxapine for the rapid non-coercive tranquilization of acute behavioral disturbances in schizophrenia patients, and beyond. ( Baloche, E; Corruble, E; Llorca, PM; Nuss, P; P Garay, R, 2022) |
| "The early and correct assessment of psychomotor agitation (PMA) is essential to ensure prompt intervention by healthcare professionals to improve the patient's condition, protect healthcare staff, and facilitate future management." | 2.72 | The Management of Psychomotor Agitation Associated with Schizophrenia or Bipolar Disorder: A Brief Review. ( De Berardis, D; Ducci, G; Galluzzo, A; Palumbo, C; Pompili, M; Rosso, G, 2021) |
| "Loxapine is a first generation antipsychotic, belonging to the dibenzoxazepine class." | 2.55 | The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review. ( Carano, A; de Bartolomeis, A; de Berardis, D; Di Giannantonio, M; Fornaro, M; Iasevoli, F; Marini, S; Martinotti, G; Orsolini, L; Perna, G; Piersanti, M; Serroni, N; Tomasetti, C; Valchera, A; Vellante, F, 2017) |
| "Loxapine is a first-generation antipsychotic medication available in the United States in oral form for more than three decades." | 2.49 | Safety and efficacy review of inhaled loxapine for treatment of agitation. ( Currier, G; Walsh, P, 2013) |
| "Loxapine is a well-established, first-generation antipsychotic agent." | 2.49 | Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. ( Keating, GM, 2013) |
| "Loxapine is an older first-generation antipsychotic drug that is approved for the treatment of schizophrenia." | 1.38 | Now take a deep breath: inhaled loxapine for the treatment of acute agitation. ( Howland, RH, 2012) |
| "Loxapine was safe and effective in treating agitation in a small group of mechanically ventilated patients and improved respiratory physiologic parameters, enabling the weaning process to be pursued." | 1.36 | Beneficial effects of loxapine on agitation and breathing patterns during weaning from mechanical ventilation. ( Bertrand, F; Chevrel, G; Dreyfuss, D; Hurel, D; Margetis, D; Ricard, JD; Sztrymf, B, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.44) | 18.7374 |
| 1990's | 1 (2.44) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 35 (85.37) | 24.3611 |
| 2020's | 4 (9.76) | 2.80 |
| Authors | Studies |
|---|---|
| Nuss, P | 1 |
| Corruble, E | 1 |
| Baloche, E | 1 |
| P Garay, R | 1 |
| Llorca, PM | 1 |
| Citrome, L | 4 |
| Pompili, M | 1 |
| Ducci, G | 1 |
| Galluzzo, A | 1 |
| Rosso, G | 1 |
| Palumbo, C | 1 |
| De Berardis, D | 2 |
| Ruch, T | 1 |
| Nuss, S | 1 |
| Yeruva, RR | 1 |
| Gao, Y | 1 |
| Tegin, G | 1 |
| Terrell, C | 1 |
| El-Mallakh, RS | 1 |
| San, L | 2 |
| Estrada, G | 2 |
| Oudovenko, N | 2 |
| Vieta, E | 2 |
| Jørgensen, TR | 2 |
| Emborg, C | 2 |
| Dahlen, K | 2 |
| Bøgelund, M | 2 |
| Carlborg, A | 2 |
| Cester-Martínez, A | 1 |
| Cortés-Ramas, JA | 1 |
| Borraz-Clares, D | 1 |
| Pellicer-Gayarre, M | 1 |
| Gaudry, S | 1 |
| Sztrymf, B | 2 |
| Sonneville, R | 1 |
| Megarbane, B | 1 |
| Van Der Meersch, G | 1 |
| Vodovar, D | 1 |
| Cohen, Y | 1 |
| Ricard, JD | 2 |
| Hajage, D | 1 |
| Salomon, L | 1 |
| Dreyfuss, D | 2 |
| Amodeo, G | 1 |
| Fagiolini, A | 1 |
| Sachs, G | 1 |
| Erfurth, A | 1 |
| Montañés, F | 1 |
| Dobrovolskaya, N | 1 |
| Bukhanovskaya, O | 1 |
| Popov, M | 1 |
| Gil, E | 1 |
| Garcia-Alonso, F | 1 |
| Boldeanu, A | 1 |
| Baleeiro Teixeira, T | 1 |
| Patrizi, B | 1 |
| Navarro-Haro, MV | 1 |
| Gasol, M | 1 |
| Cole, JB | 1 |
| Klein, LR | 1 |
| Mullinax, SZ | 1 |
| Nordstrom, KD | 1 |
| Driver, BE | 1 |
| Wilson, MP | 1 |
| Pacciardi, B | 1 |
| Calcedo, A | 1 |
| Messer, T | 1 |
| Owen, RT | 1 |
| Currier, G | 1 |
| Walsh, P | 1 |
| Keating, GM | 1 |
| Juckel, G | 1 |
| Passmore, MJ | 1 |
| Virani, A | 1 |
| Hendel, K | 1 |
| Morrow, T | 1 |
| Jaffe, R | 1 |
| Siniscalchi, M | 1 |
| Cruz-Luna, N | 1 |
| Cosgrove, D | 1 |
| Kahl, KG | 2 |
| Negt, P | 2 |
| Wollmer, A | 1 |
| Jung, S | 2 |
| Kruger, TH | 2 |
| Wollmer, MA | 1 |
| Frieling, H | 1 |
| Zeller, SL | 1 |
| Pollack, CV | 1 |
| Shader, RI | 1 |
| Fornaro, M | 1 |
| Orsolini, L | 1 |
| Iasevoli, F | 1 |
| Tomasetti, C | 1 |
| de Bartolomeis, A | 1 |
| Serroni, N | 1 |
| Valchera, A | 1 |
| Carano, A | 1 |
| Vellante, F | 1 |
| Marini, S | 1 |
| Piersanti, M | 1 |
| Perna, G | 1 |
| Martinotti, G | 1 |
| Di Giannantonio, M | 1 |
| Chevrel, G | 1 |
| Bertrand, F | 1 |
| Margetis, D | 1 |
| Hurel, D | 1 |
| Lesem, MD | 2 |
| Tran-Johnson, TK | 1 |
| Riesenberg, RA | 2 |
| Feifel, D | 2 |
| Allen, MH | 3 |
| Fishman, R | 1 |
| Spyker, DA | 3 |
| Kehne, JH | 2 |
| Cassella, JV | 3 |
| Zimbroff, DL | 1 |
| Ross, R | 1 |
| Munzar, P | 1 |
| Eiden, C | 1 |
| Capdevielle, D | 1 |
| Deddouche, C | 1 |
| Boulenger, JP | 1 |
| Blayac, JP | 1 |
| Peyrière, H | 1 |
| Shepherd, AR | 1 |
| Gallagher, R | 1 |
| Howland, RH | 1 |
| Kwentus, J | 1 |
| Marandi, M | 1 |
| Manning, RA | 1 |
| Fishman, RS | 1 |
| Buckley, PF | 1 |
| Fruensgaard, K | 1 |
| Korsgaard, S | 1 |
| Jorgensen, H | 1 |
| Jensen, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Loxapine in the Management of Restlessness During Mechanical Ventilation Weaning[NCT01193816] | Phase 4 | 100 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| A Phase IV, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety of Self-administered ADASUVE® (Staccato Loxapine for Inhalation) in Agitated Patients Outside the Hospital Setting[NCT02525991] | Phase 4 | 323 participants (Actual) | Interventional | 2016-09-08 | Completed | ||
| An Observational Study of Anti-Psychotic Medication for the Treatment of Agitation in the Emergency Department[NCT02877108] | 100 participants (Anticipated) | Observational | 2016-04-30 | Recruiting | |||
| An Open-Label, Randomized, Active Controlled Inpatient Trial Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder[NCT06093451] | Phase 4 | 32 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Schizophrenic Patients With Agitation[NCT00628589] | Phase 3 | 344 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Multi-center, Randomized, Double-blind, Placebo-controlled, Single Dose Efficacy and Safety Study of StaccatoTM Loxapine for Inhalation in Schizophrenic Patients With Agitation.[NCT00369577] | Phase 2 | 129 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Patients With Bipolar I Disorder and Acute Agitation[NCT00721955] | Phase 3 | 314 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Frequency of response based on the CGI-I (defined as achieving a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation) (NCT00628589)
Timeframe: Baseline and 2 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Placebo | 41 |
| Inhaled Loxapine 5 mg | 66 |
| Inhaled Loxapine 10 mg | 75 |
The Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (min) to 7 (max). The PANSS-EC, the sum of these 5 subscales, thus ranges from 5 to 35. Individuals were eligible if they had a PANSS-EC of ≥14 (out of 35) and a score ≥4 (out of 7) on at least 1 of the 5 items. (NCT00628589)
Timeframe: Baseline and 2 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Inhaled Placebo | -5.5 |
| Inhaled Loxapine 5 mg | -8.1 |
| Inhaled Loxapine 10 mg | -8.6 |
Clinical Global Impression- Improvement (CGI-I) scores ranged from 1 to 7: 0=not assessed (missing), 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. (NCT00628589)
Timeframe: Baseline and 2 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Inhaled Placebo | 2.8 |
| Inhaled Loxapine 5 mg | 2.3 |
| Inhaled Loxapine 10 mg | 2.1 |
Change from baseline on the Behavioral Activity Rating Scale (BARS) ranging from 1 to 7 where: 1 = difficult or unable to rouse, 2 = asleep but responds normally to verbal or physical contact, 3 = drowsy, appears sedated, 4 = quiet, and awake (normal level of activity), 5 = signs of overt (physical or verbal) activity, calms down with instructions, 6 = extremely or continuously active, not requiring restraint, 7 = violent, requires restraint. (NCT00369577)
Timeframe: 2 hours
| Intervention | BARS Score, Change from Baseline, units (Mean) |
|---|---|
| Inhaled Placebo | -0.930 |
| Inhaled Loxapine 5 mg | -1.53 |
| Inhaled Loxapine 10 mg | -2.02 |
Frequency of response based on the CGI-I (defined as achieving a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation) (NCT00369577)
Timeframe: 2 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Placebo | 9 |
| Inhaled Loxapine 5 mg | 22 |
| Inhaled Loxapine 10 mg | 25 |
Clinical Global Impression- Improvement (CGI-I) scores ranged from 1 to 7: 0=not assessed (missing), 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. (NCT00369577)
Timeframe: 2 hours
| Intervention | CGI-I Units (7=worse, 1=better) (Mean) |
|---|---|
| Inhaled Placebo | 3.19 |
| Inhaled Loxapine 5 mg | 2.53 |
| Inhaled Loxapine 10 mg | 2.28 |
The Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (min) to 7 (max). The PANSS-EC, the sum of these 5 subscales, thus ranges from 5 to 35. Individuals were eligible if they had a PANSS-EC of ≥14 (out of 35) and a score ≥4 (out of 7) on at least 1 of the 5 items. (NCT00369577)
Timeframe: 2 hours
| Intervention | PANSS units (Mean) |
|---|---|
| Inhaled Placebo | -4.98 |
| Inhaled Loxapine 5 mg | -6.71 |
| Inhaled Loxapine 10 mg | -8.56 |
Frequency of response based on the CGI-I (defined as achieving a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation) (NCT00721955)
Timeframe: Baseline and 2 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Placebo | 29 |
| Inhaled Loxapine 5 mg | 69 |
| Inhaled Loxapine 10 mg | 78 |
The Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (min) to 7 (max). The PANSS-EC, the sum of these 5 subscales, thus ranges from 5 to 35. Individuals were eligible if they had a PANSS-EC of ≥14 (out of 35) and a score ≥4 (out of 7) on at least 1 of the 5 items. (NCT00721955)
Timeframe: Baseline and 2 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Inhaled Placebo | -4.9 |
| Inhaled Loxapine 5 mg | -8.1 |
| Inhaled Loxapine 10 mg | -9.0 |
Clinical Global Impression- Improvement (CGI-I) scores ranged from 1 to 7: 0=not assessed (missing), 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. (NCT00721955)
Timeframe: Baseline and 2 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Inhaled Placebo | 3.0 |
| Inhaled Loxapine 5 mg | 2.1 |
| Inhaled Loxapine 10 mg | 1.9 |
14 reviews available for loxapine and Agitation, Psychomotor
| Article | Year |
|---|---|
Fifty years of experience with loxapine for the rapid non-coercive tranquilization of acute behavioral disturbances in schizophrenia patients, and beyond.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Humans; Loxapine; Psychomotor Ag | 2022 |
Agitation in schizophrenia: origins and evidence-based treatment.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Evidence-Based Medicine; Humans; Loxapine; Psycho | 2021 |
The Management of Psychomotor Agitation Associated with Schizophrenia or Bipolar Disorder: A Brief Review.
Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Loxapine; Psychomotor Agitation; Schizophrenia | 2021 |
Older and Newer Strategies for the Pharmacological Management of Agitation in Patients with Bipolar Disorder or Schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Loxapine; Psychomotor Agitation; Sc | 2017 |
Inhaled Loxapine for the Management of Acute Agitation in Bipolar Disorder and Schizophrenia: Expert Review and Commentary in an Era of Change.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Humans; Loxapine; Psychomotor Ag | 2019 |
Safety and efficacy review of inhaled loxapine for treatment of agitation.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Humans; Loxapine; Psychomotor Ag | 2013 |
Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Drug Delivery Systems; Dry Powde | 2013 |
Inhaled loxapine (Adasuve) for acute agitation.
Topics: Administration, Inhalation; Animals; Antipsychotic Agents; Bronchial Spasm; Humans; Loxapine; Psycho | 2014 |
Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Disease Management; Emergency Se | 2016 |
Inhaled loxapine for the urgent treatment of acute agitation associated with schizophrenia or bipolar disorder.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Humans; Loxapine; Psychomotor Ag | 2016 |
The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Inhalation; Loxapine; Mental Disorders; Psyc | 2017 |
Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder.
Topics: Administration, Inhalation; Aerosols; Antipsychotic Agents; Bipolar Disorder; Humans; Loxapine; Nebu | 2011 |
Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
Topics: Administration, Inhalation; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Clinical Trials, Ph | 2012 |
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Loxapine; Mental Disorders; Ol | 1999 |
8 trials available for loxapine and Agitation, Psychomotor
| Article | Year |
|---|---|
Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Aripiprazole; | 2017 |
Loxapine to control agitation during weaning from mechanical ventilation.
Topics: Aged; Antipsychotic Agents; Double-Blind Method; Female; Humans; Loxapine; Male; Middle Aged; Placeb | 2017 |
PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Dis | 2018 |
Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting: protocol for a phase IV, single-arm, open-label trial.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Clinical Trials, Phase IV as Top | 2018 |
Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Respo | 2011 |
Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Inhalation; Adult; Aerosols; Antipsychotic Agents; Double-Blind Method; Drug Adminis | 2011 |
Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine.
Topics: Administration, Inhalation; Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Fema | 2012 |
Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study.
Topics: Acute Disease; Adult; Aged; Aggression; Biperiden; Clinical Trials as Topic; Dibenzoxazepines; Doubl | 1977 |
19 other studies available for loxapine and Agitation, Psychomotor
| Article | Year |
|---|---|
Inhaled loxapine for acute agitation in a psychiatric emergency service.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Emergency Services, Psychiatric; | 2021 |
Patient preferences for medicine administration for acute agitation: results from an internet-based survey of patients diagnosed with bipolar disorder or schizophrenia in two Nordic countries.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Denmark; Drug Administration Routes; Female; Humans; | 2018 |
[New medical approach to out-of-hospital treatment of psychomotor agitation in psychiatric patients: a report of 14 cases].
Topics: Administration, Inhalation; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Drug Evaluation; Em | 2017 |
Inhaled loxapine for agitation in patients with personality disorder: an initial approach.
Topics: Administration, Inhalation; Adolescent; Adult; Antipsychotic Agents; Databases, Factual; Female; Hum | 2019 |
Study Enrollment When "Preconsent" Is Utilized for a Randomized Clinical Trial of Two Treatments for Acute Agitation in the Emergency Department.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Emergency Service, Hospital; Ethics, Research; Female | 2019 |
Inhaled loxapine: a new treatment for agitation in schizophrenia or bipolar disorder.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Drug Delivery Systems; Humans; L | 2013 |
[Inhalative loxapine: old tried and trusted medication with new indications].
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Evidence-Based Medicine; Humans; | 2013 |
Antipsychotic options for delirium-related agitation--a multidisciplinary practitioner survey.
Topics: Antipsychotic Agents; British Columbia; Cooperative Behavior; Delirium; Drug Substitution; Health Su | 2013 |
Old drug in new package promises to calm the agitated.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Humans; Loxapine; Psychomotor Ag | 2014 |
Inhaled Loxapine for ECT Pretreatment for Agitation.
Topics: Administration, Inhalation; Adult; Antipsychotic Agents; Electroconvulsive Therapy; Humans; Loxapine | 2016 |
Inhaled Loxapine for Acute Treatment of Agitation in Patients With Borderline Personality Disorder: A Case Series.
Topics: Acute Disease; Administration, Inhalation; Adult; Antipsychotic Agents; Borderline Personality Disor | 2015 |
[Inhaled loxapine for emergency treatment of agitated patients with borderline personality disorder : A series of five cases].
Topics: Administration, Inhalation; Adult; Antipsychotic Agents; Borderline Personality Disorder; Emergency | 2016 |
The effect of the medicine administration route on health-related quality of life: Results from a time trade-off survey in patients with bipolar disorder or schizophrenia in 2 Nordic countries.
Topics: Administration, Inhalation; Administration, Oral; Adult; Antipsychotic Agents; Bipolar Disorder; Fem | 2016 |
ClinicalTrials.gov, Inhaled Loxapine, and Safety Issues.
Topics: Administration, Inhalation; Antipsychotic Agents; Clinical Trials as Topic; Humans; Internet; Loxapi | 2017 |
Beneficial effects of loxapine on agitation and breathing patterns during weaning from mechanical ventilation.
Topics: Aged; Antipsychotic Agents; Female; Hospitals, University; Humans; Intensive Care Units; Loxapine; M | 2010 |
Neuroleptic malignant syndrome-like reaction precipitated by antipsychotics in a patient with gamma-butyrolactone withdrawal.
Topics: 4-Butyrolactone; Adult; Antipsychotic Agents; Clonazepam; Diagnosis, Differential; Drug Evaluation, | 2011 |
The benefits of an active control arm.
Topics: Antipsychotic Agents; Female; Humans; Loxapine; Male; Psychomotor Agitation; Schizophrenia | 2011 |
Swallowing difficulties: a prognostic signpost.
Topics: Aged, 80 and over; Analgesics, Opioid; Antipsychotic Agents; Back Pain; Chronic Pain; Deglutition Di | 2011 |
Now take a deep breath: inhaled loxapine for the treatment of acute agitation.
Topics: Acute Disease; Administration, Inhalation; Aerosols; Antipsychotic Agents; Bipolar Disorder; Dose-Re | 2012 |